Type | Public | |
Founded | 2005 | |
HQ | Tokyo, JP | Map |
Website | daiichisankyo.com | |
Employee Ratings | More |
JPY | |
---|---|
Revenue (Q3, 2022) | 281.0b |
Gross profit (Q3, 2022) | 203.3b |
Net income (Q3, 2022) | 31.9b |
EBITDA (Q3, 2022) | 53.3b |
EBIT (Q3, 2022) | 39.1b |
Market capitalization (12-May-2022) | 5.7t |
Closing stock price (12-May-2022) | 3.2k |
Cash (31-Dec-2021) | 577.3b |
EV | 5.3t |
JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 960.2b | 929.7b | 981.8b | 962.5b |
Cost of goods sold | (299.3b) | (318.4b) | (290.6b) | (280.9b) |
Gross profit | 660.9b | 611.3b | 691.2b | 681.6b |
R&D expense | (236.0b) | (203.7b) | (197.5b) | (227.4b) |
JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 225.7b | 221.1b | 256.2b | 249.2b | 230.3b | 277.5b | 236.9b | 243.2b | 258.6b | 264.1b | 265.9b | 281.0b |
Cost of goods sold | (73.5b) | (70.5b) | (86.6b) | (75.0b) | (75.8b) | (66.4b) | (68.1b) | (72.0b) | (73.4b) | (70.5b) | (73.1b) | (77.7b) |
Gross profit | 152.2b | 150.6b | 169.7b | 174.3b | 154.6b | 211.1b | 168.9b | 171.2b | 185.2b | 193.6b | 192.8b | 203.3b |
R&D expense | (45.5b) | (48.2b) | (48.9b) | (41.2b) | (44.7b) | (51.1b) | (48.8b) | (55.7b) | (59.1b) | (54.0b) | (55.0b) | (60.1b) |
JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 258.2b | 154.9b | 280.4b | 294.8b |
Accounts Receivable | 210.8b | 360.4b | 282.5b | 201.0b |
Inventories | 172.6b | 176.1b | 173.4b | 200.9b |
JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 294.0b | 236.9b | 239.2b | 260.9b | 297.6b | 326.4b | 382.1b | 451.3b | 520.1b | 352.3b | 550.1b | 577.3b |
Accounts Receivable | 230.1b | 270.8b | 305.7b | 356.8b | 342.5b | 351.9b | 243.9b | 252.8b | 263.4b | 258.1b | 276.5b | 282.9b |
Inventories | 184.1b | 186.6b | 177.6b | 186.0b | 177.4b | 172.7b | 183.7b | 183.3b | 183.9b | 211.8b | 210.0b | 211.6b |
JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | 81.0b | 85.8b | 141.2b | 74.1b |
Depreciation and Amortization | 46.7b | 46.2b | 52.6b | 57.4b |
Inventories | (19.4b) | (4.0b) | (7.4b) | (21.2b) |
Accounts Payable | 238.0m | 60.4b | (44.7b) | 23.9b |
JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 29.6b | 58.6b | 98.0b | 57.1b | 87.0b | 160.0b | 41.4b | 67.0b | 99.6b | 47.1b | 86.0b | 125.9b |
Depreciation and Amortization | 11.2b | 22.6b | 34.3b | 12.9b | 26.4b | 39.2b | 14.1b | 28.5b | 42.9b | 14.7b | 29.0b | 43.2b |
Inventories | (11.1b) | (12.1b) | (5.0b) | (12.5b) | (11.7b) | (4.9b) | (10.4b) | (10.2b) | (11.2b) | (10.1b) | (7.7b) | (6.0b) |
Accounts Payable | (27.4b) | 3.8b | 8.2b | (23.9b) | (59.0b) | (85.5b) | (30.3b) | (22.0b) | (19.1b) | (33.9b) | (33.0b) | (23.4b) |
JPY | FY, 2018 |
---|---|
Revenue/Employee | 66.5m |
Company Name | Date | Deal Size |
---|---|---|
Im Co | October 08, 2015 | |
Rice Force | October 08, 2015 | |
Ambit Biosciences | September 29, 2014 | $410 m |
Plexxikon Inc. | April 04, 2011 | $935 m |
Ranbaxy Laboratories | November 30, 2008 | $4.6 b |
U3 Pharma AG | May 26, 2008 | |
Ambit Biosciences Corp. | ||
American Regent, Inc. | ||
Daiichi Sankyo | ||
Daiichi Sankyo Biotech Co., Ltd. |
Daiichi Sankyo revenue breakdown by business segment: 92.8% from PHARMACEUTICAL DIVERSIFIED, 7.0% from HEALTHCARE and 0.2% from Other
Daiichi Sankyo has 624 Twitter Followers. The number of followers has increased 0.8% month over month and increased 2.2% quarter over quarter
When was Daiichi Sankyo founded?
Daiichi Sankyo was founded in 2005.
Who are Daiichi Sankyo key executives?
Daiichi Sankyo's key executives are Sunao Manabe, Satoru Kimura and Masahiko Ohtsuki.
How many employees does Daiichi Sankyo have?
Daiichi Sankyo has 16,033 employees.
What is Daiichi Sankyo revenue?
Latest Daiichi Sankyo annual revenue is ¥962.5 b.
What is Daiichi Sankyo revenue per employee?
Latest Daiichi Sankyo revenue per employee is ¥60 m.
Who are Daiichi Sankyo competitors?
Competitors of Daiichi Sankyo include Bayer, Bristol-Myers Squibb and Boehringer Ingelheim.
Where is Daiichi Sankyo headquarters?
Daiichi Sankyo headquarters is located at 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo.
Where are Daiichi Sankyo offices?
Daiichi Sankyo has offices in Tokyo, Chiba, Chiyoda, Chuo City and in 39 other locations.
How many offices does Daiichi Sankyo have?
Daiichi Sankyo has 47 offices.
Receive alerts for 300+ data fields across thousands of companies